Venous thromboembolism during pregnancy, postpartum or during contraceptive use

Journal: Thrombosis and Haemostasis
ISSN: 0340-6245
Issue: 2010: 103/2 (Feb) pp. 251–479
Pages: 306-311

Venous thromboembolism during pregnancy, postpartum or during contraceptive use

Findings from the RIETE Registry

A. Blanco-Molina (1), L. L. Rota (2), P. Di Micco (3), B. Brenner (4), J. Trujillo-Santos (5), A. Ruiz-Gamietea (6), M. Monreal (7); for the RIETE Investigators

(1) Department of Internal Medicine, Hospital Universitario Reina Sofía, Córdoba, Spain; (2) Department of Thrombosis, Istituto Cliinico Humanitas IRCCS, Rozzano, Milan, Italy; (3) Department of Internal Medicine, Ospedale Buonconsiglio Fatebenefratelli, Naples, Italy; (4) Department of Haematology, Rambam Medical Center, Haifa, Israel; (5) Departmentof Internal Medicine, Hospital Universitario Santa María de Rosell, Cartagena, Murcia, Spain; (6) Department of Internal Medicine, Hospital Universitario Joan XXIII de Tarragona,Tarragona, Spain; (7) Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain


venous thromboembolism, pregnancy, Contraceptives, postpartum


Venous thromboembolism (VTE) is a leading cause of maternal death during pregnancy or postpartum, and in women using hormonal contraceptives. However, important issues concerning its natural history and therapy remain unsolved, and most of the protocols for treatment of VTE in this patient population are based on data extrapolated from other populations. RIETE is an ongoing registry of consecutive patients with objectively confirmed, symptomatic, acute VTE. We examined the clinical characteristics and three-month outcome of all enrolled women with pregnancy, postpartum or using hormonal contraceptives. As of December 2008, 173 pregnant women, 135 postpartum, and 798 contraceptive users were enrolled. Of these, 438 (40%) presented with pulmonary embolism (PE) and 668 with deep-vein thrombosis (DVT). Most women with acute PE had dyspnea (72%) or chest pain (75%), but only 2.0% had hypoxaemia. During the three-month study period, five women (0.45%; 95% CI: 0.17–1.00) died (3 had fatal PE), 13 (1.18%; 95% CI: 0.66–1.95) had VTE recurrences, and seven (0.63%; 95% CI: 0.28–1.25) major bleeding. Two of the three women with fatal PE died during the first few hours after arriving at the emergency ward, with no time to start any therapy. The outcome of pregnant or postpartum women with VTE is similar to that in contraceptive users, even though the treatment is different. The non-specific nature of PE signs may have caused some delay in PE diagnosis.

You may also be interested in...

Rupert M. Bauersachs 1, Joachim Dudenhausen 2, Andree Faridi 3, Thorsten Fischer 4, Samson Fung 5, Ulrich Geisen 6, Job Harenberg 7, Eberhard Herchenhan 8, Franz Keller 9, Bettina Kemkes-Matthes 10, Helmut Schinzel 1 1, Michael Spannagl 1 2, Christian J. Thaler 1 3, for the EThIG Investigators*

Thromb Haemost 2007 98 6: 1237-1245

Angeles Blanco-Molina 1, Javier Trujillo-Santos 2, Juan Criado 1, Luciano Lopez 1, Ramón Lecumberri 3, Reyes Gutierrez 4, Manuel Monreal 5, for the RIETE Investigators*

Thromb Haemost 2007 97 2: 186-190


Theme Issue Article to Theme Issue "GTH - State of the Art"

N. A. Horowitz (1, 2), N. Lavi (1), Y. Nadir (1, 2), B. Brenner (1, 2)

Thromb Haemost 2016 116 4: 613-617